HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Clofibrate

A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

Also Known As:

Athromidin; Atromid; Atromid S; Clofibric Acid, Ethyl Ester; Ethyl Chlorophenoxyisobutyrate; Miscleron; Miskleron; Chlorophenoxyisobutyrate, Ethyl; Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, ethyl ester

Networked: 748 relevant articles (38 outcomes, 111 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 58

Experts

1.	Miller, Richard T: 5 articles (11/2005 - 09/2005)
2.	Hoivik, Debie J: 5 articles (11/2005 - 09/2005)
3.	Pérez-Severiano, Francisca: 4 articles (05/2015 - 09/2010)
4.	Santostefano, Michael J: 4 articles (09/2005 - 09/2005)
5.	Allen, Jane S: 4 articles (09/2005 - 09/2005)
6.	Selinger, Krzysztof: 4 articles (09/2005 - 09/2005)
7.	Soria-Castro, Elizabeth: 3 articles (05/2015 - 09/2010)
8.	Nemoto, Kiyomitsu: 3 articles (02/2013 - 10/2011)
9.	Degawa, Masakuni: 3 articles (02/2013 - 10/2011)
10.	Cervantes-Pérez, Luz Graciela: 3 articles (10/2012 - 09/2010)

Related Diseases

1.	Hyperlipoproteinemias 09/01/1979 - "Platelet kinetic studies in patients with hyperlipoproteinemia: effects of clofibrate therapy." 12/01/1994 - "[Clofibrate treatment of hyperlipoproteinemia]." 08/01/1983 - "The results permit the conclusion that the use of clofibrate for the long-term treatment of hyperlipoproteinemia is still justified. " 11/01/1981 - "It is concluded that clofibrate is a strong hypolipidemic drug for the treatment of type III hyperlipoproteinemia, which does not lose efficacy even after 7 years of use." 11/01/1981 - "In this retrospective study we report the results of treatment with clofibrate during at least 7 years in 9 patients with severe type III hyperlipoproteinemia. "
2.	Myocardial Infarction 12/25/1971 - "There was a significant reduction in all events (fatal and non-fatal) in patients with angina ("all anginas") in the clofibrate-treated group; the rate was reduced by 53%.Clofibrate did not alter the overall mortality or morbidity rates in patients admitted to the trial with recent myocardial infarction without preceding angina of more than three months' duration. " 12/01/1988 - "Improved myocardial performance induced by clofibrate during reperfusion after acute myocardial infarction." 01/01/1982 - "Clofibrate also moderated the cellular immune response in patients with myocardial infarction or peripheral arterial illness. " 11/29/1978 - "[Myocardial infarct and clofibrate--again]." 11/29/1978 - "[Serum lipid reduction with clofibrate reduces the incidence of myocardial infarct]."
3.	Hyperlipidemias (Hyperlipidemia) 03/10/1979 - "Clofibrate or derivatives proved effective in cases where hyperlipemia failed to respond to dietary measures." 06/24/1969 - "[Studies on lipemia in elderly persons and the lipid lowering effect of a clofibrate derivate in 2 groups of test persons]." 09/01/1983 - "Clofibrate is the drug of choice for the rare Type III hyperlipidemia. " 07/01/1981 - "Comparative effect of clofibrate, garlic and onion on alimentary hyperlipemia." 09/01/1980 - "The mechanism of formation of the perigraft lipid accumulation and the relationship of this unusual sequence of complications to the hyperlipidemia or its treatment with clofibrate are discussed."
4.	Neoplasms (Cancer) 09/01/1992 - "These reassuring observations contradict those of the WHO study with clofibrate: a significant increase in the incidence of cancer, especially gastrointestinal, is observed in the treatment group. " 03/01/2015 - "Clofibrate is categorized as a Group 3 chemical by the International Agency for Research on Cancer and is considered a non-genotoxic carcinogen. " 01/01/2013 - "Clofibrate induces HO-1 gene expression in cancer cells through a PPARα-independent mechanism and the Nrf2 signaling pathway is indispensible for this induction." 01/01/2010 - "The present review will focus on the cytotoxic effects exerted by several PPs, among which clofibrate, on different types of tumor cells, with particular reference to the mechanisms of cell death and to their relevance to cancer induction and progression." 04/03/2008 - "Decreases in hepatic NQO1 in livers of animals fed clofibrate were noted before the appearance of mammary tumors. "
5.	Ischemia 04/15/2006 - "Functional study showed that hearts from clofibrate-treated rats had an improved recovery of post-ischemic contractile function and reduced ischemia/reperfusion (I/R)-induced infarct size. " 12/01/1988 - "This study was designed to examine whether a hypolipidemic drug such as clofibrate can reduce the myocardial injury during ischemia and reperfusion. " 03/01/1978 - "Pre-treatment with clofibrate caused a definite improvement in survival, less shock and prostration, and ECG evidence of little or no ischemia. " 12/01/2002 - "The aim of this study was to investigate the effects of peroxisome-proliferator activated receptor-alpha (PPAR-alpha) agonists, clofibrate and WY14643 on the renal dysfunction and injury caused by bilateral ischemia/reperfusion (I/R) of rat kidneys in vivo. " 05/01/2015 - "Expression of the angiotensin-converting enzyme increased during ischemia, whereas clofibrate-treated group remained comparable to control. "

Related Drugs and Biologics

1.	Gemfibrozil (Lopid)
2.	Clofibrate
3.	Niacin (Nicotinic Acid)
4.	Enzymes
5.	Fibric Acids (Fibrates)
6.	Dipyridamole (Persantine)
7.	Lovastatin (Mevacor)
8.	Clofibric Acid
9.	Cholesterol
10.	Bezafibrate

Related Therapies and Procedures

1.	Phototherapy (Light Therapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Aftercare (After-Treatment)
4.	Caloric Restriction
5.	Jejunoileal Bypass